Log in to search using one of your social media accounts:

 

Supporting opportunities for enhanced competition in the marketplace
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into the marketplace. Thanks in part to the incentives in the law, 90 percent of prescriptions today are filled with generics. And for brand medicines facing generic entry in most recent data from 2013-2014, generics captured an average of 93 percent of the market (by volume) within a year of entry. This dynamic of robust generic marketplace uptake and competition is only set to increase in time. All the while,multiple sources confirm ...
Source: The Catalyst - November 22, 2017 Category: Pharmaceuticals Tags: FDA Intellectual Property REMS Source Type: news

New report shows better diabetes management saves money and improves patient outcomes
A recent IHS Markit report, “The Clinical and Economic Benefits of Better Treatment of Adult Medicaid Beneficiaries with Diabetes, ” simulated savings in the Medicaid program as a result of better management of diabetes. The study found that controlling blood pressure, total cholesterol and HbA1C (a key blood sugar metric) significantly reduced the onset of several chronic conditions for patients with diabetes and could save more than $4 billion based on Medicaid health care spending in 2016. (Source: The Catalyst)
Source: The Catalyst - November 21, 2017 Category: Pharmaceuticals Tags: diabetes health care spending Medicaid Ask About Adherence Medication Adherence Source Type: news

Medicare Monday: PhRMA ’s comments on new direction for CMMI
Today, PhRMA submitted its comments in response to the Centers for Medicare& Medicaid Services (CMS) request for information on the future of the Center for Medicare and Medicaid Innovation (CMMI). While well intentioned, CMMI ’s current flexibility to make far-reaching changes has raised a number of concerns about large-scale mandatory demonstrations developed without stakeholder input, such as theproposed Part B drug payment model that was recently withdrawn. We welcome the Administration ’s call for feedback and look forward to working with them on the evolution of CMMI. Here are some of our suggestions ...
Source: The Catalyst - November 20, 2017 Category: Pharmaceuticals Tags: Medicare CMMI Source Type: news

Medicare Monday: Same bad ideas continue to threaten Part D and beneficiary access to medicines
Perhaps the biggest fact that is often overlooked about Part D is that there is already significant price negotiation in the program. Thanks to Part D ’s competitive structure, large purchasers oftennegotiate steep discounts and rebates with prescription drug manufacturers. This robust competition and negotiation consistently keeps costs low for beneficiaries and taxpayers. TheMedicare Trustees report negotiated rebates have increased every year of the program and premiums have remained stable since 2011. In fact, average monthlypremiums are expected to decrease in 2018. (Source: The Catalyst)
Source: The Catalyst - November 13, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

Video: What is a results-based contract?
New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies are working with insurers to develop new ways to pay for medicines. (Source: The Catalyst)
Source: The Catalyst - November 13, 2017 Category: Pharmaceuticals Authors: Katie Koziara Tags: Access Value drug cost Value-Driven Health Care The Value Collaborative Source Type: news

Honoring veterans serving in the biopharmaceutical industry
In honor of Veterans Day, we spoke with Rob Caskey, a senior manager in PhRMA ’s finance department about his military service, journey to PhRMA and why veterans make great employees for America’s biopharmaceutical companies. (Source: The Catalyst)
Source: The Catalyst - November 11, 2017 Category: Pharmaceuticals Source Type: news

New report and event examine the new era of vaccines
Today, leading minds will come together for an in-depth conversation centered on vaccines – their critical role in warding off disease, the innovative science powering breakthroughs in their research and what their future might look like. (Source: The Catalyst)
Source: The Catalyst - November 9, 2017 Category: Pharmaceuticals Tags: Research and Development Vaccines New Era of Medicine GoBoldly Source Type: news

A new era in cancer
The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment. Next week, on Wednesday, November 8, leading minds in the fight against cancer will come together in Philadelphia for a conversation led byAxios titled, “Future Shapers: A New Era in Cancer Care.” The event is sponsored as part of PhRMA’s GOBOLDLY campaign. (Source: The Catalyst)
Source: The Catalyst - November 1, 2017 Category: Pharmaceuticals Tags: Research and Development cancer New Era of Medicine GoBoldly Source Type: news

Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI
In case you missed it, earlier this month, the Center for Medicare& Medicaid Services formallywithdrew a controversial proposal that would have had a detrimental impact on patient access to lifesaving treatments covered under Part B, many of which are used to treat complex conditions like cancer, rheumatoid arthritis and mental illness. (Source: The Catalyst)
Source: The Catalyst - October 30, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B CMMI Source Type: news

Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes
Ask About Adherence is a blog series featuring Q&A ’s with experts and new medication adherence resources. In this post, we feature a recent study comparing the effectiveness of oral and injectable disease-modifying therapies for patients with multiple sclerosis. (Source: The Catalyst)
Source: The Catalyst - October 24, 2017 Category: Pharmaceuticals Tags: chronic disease Multiple Sclerosis Ask About Adherence Source Type: news

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have taken notice. Just last week, the House Energy and Commerce Subcommittee on Oversight and Investigations held ahearing to examine how the 340B program is being used by 340B covered entities, including grantees and hospitals. (Source: The Catalyst)
Source: The Catalyst - October 20, 2017 Category: Pharmaceuticals Tags: Patients 340B hospitals 340B Spotlight Source Type: news

The Washington Post retracts PhRMA claim in opioid story
Earlier this week,The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its enactment. As stated previously, theseclaims are unequivocally false and last nightTheWashington Post issued a correction clarifying that PhRMA did not take a position on the legislation. (Source: The Catalyst)
Source: The Catalyst - October 18, 2017 Category: Pharmaceuticals Tags: Prescription Drug Safety Rx Drug Abuse Source Type: news

Excerpts from testimony by PhRMA ’s Lori Reilly
Today, Lori Reilly, executive vice president for policy, research and membership at the Pharmaceutical Research and Manufacturers of America (PhRMA), testified at the U.S. Senate Committee on Health, Education Labor and Pensions about understanding the role the drug delivery system plays in determining what patients pay for medicines.  (Source: The Catalyst)
Source: The Catalyst - October 17, 2017 Category: Pharmaceuticals Tags: drug cost Source Type: news

How much are hospitals marking up the price of medicines? The answer may surprise you.
Hospitals mark up medicine prices, on average, nearly 500 percent, according to anew analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). The analysis of 20 medicines also found the amount hospitals receive after negotiations with commercial payers is, on average, more than 250 percent what they paid to acquire the medicine. This means a hospital is paid two and a half times what the biopharmaceutical company, who brought the medicine to market, receives. This hidden threat to affordability is a driver of higher cost sharing and premiums for patients acr...
Source: The Catalyst - October 17, 2017 Category: Pharmaceuticals Tags: Access 340B hospitals Source Type: news

Medicare Monday: Open enrollment is here again
It ’s that time of year again: Medicare open enrollment!As of Sunday, October 15, newly qualified patients and current Medicare beneficiaries can review their coverage options and select their 2018 plans. The Medicare open enrollment period will run through Thursday, December 7.So what do you need to know about open enrollment? (Source: The Catalyst)
Source: The Catalyst - October 16, 2017 Category: Pharmaceuticals Tags: Part D Medicare open enrollment Medicare Monday Source Type: news

PhRMA response to Washington Post and 60 Minutes stories
The opioid epidemic confronting America is a growing public health crisis from which none of us are immune. Its impact is felt by families across the country, in small towns and large cities, coast to coast and everywhere in-between. Addressing this crisis requires a multifaceted solution involving everyone —parents and teachers, prescribers, biopharmaceutical companies, mental health professionals, those involved in distributing controlled substances and federal and state agencies. (Source: The Catalyst)
Source: The Catalyst - October 16, 2017 Category: Pharmaceuticals Tags: Prescription Drug Safety Rx Drug Abuse Source Type: news

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
PhRMA president and CEO Stephen J. Ubl joinedFox Business ’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as part of its commitment to advance a multifaceted solution to address the opioid crisis. Most recently, PhRMA announced its support forpolicies limiting the supply of opioids to seven days for acute pain treatment. (Source: The Catalyst)
Source: The Catalyst - October 12, 2017 Category: Pharmaceuticals Tags: Safety FDA Patients Prescription Drug Safety Source Type: news

PhRMA, member companies and NIH create public-private partnership for immuno-oncology
The rapid pace of scientific advances has helped usher in anew era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took asignificant step in advancing this new era by partnering with PhRMA and nine of its member companies to create the Partnership for Accelerating Cancer Therapies (PACT), a five-year research collaboration totaling $215 million as part of the Cancer Moonshot initiative. This public-private partnership will be managed by the Foundation for the National Institutes of Health. (Source: The Catalyst)
Source: The Catalyst - October 12, 2017 Category: Pharmaceuticals Tags: Research and Development cancer Source Type: news

2017 Research & Hope Awards honor innovators in mental health
Mental health disorders are a heavy human and economic burden in the United States. More than 40 million people across the country are impacted by mental illness, and it ’s estimated that in any given year there are more than $300 billion in direct and indirect costs to the U.S. economy related to mental illness. (Source: The Catalyst)
Source: The Catalyst - October 10, 2017 Category: Pharmaceuticals Tags: Medicines in Development Research and Development GoBoldly Source Type: news

PhRMA Foundation recognizes inaugural Challenge Award recipients
Last month, thePhRMA Foundation announced the recipients of the inauguralChallenge Awards atMorning Consult. These awards recognize the best and the brightest that are identifying transformative solutions to measure value in health care and advance a value-driven health care system. The Challenge Awards are the first phase in the multi-yearValue Assessment Initiative that will award over $1 million to advance the field of value assessment. (Source: The Catalyst)
Source: The Catalyst - October 6, 2017 Category: Pharmaceuticals Tags: PhRMA Foundation Value-Driven Health Care Source Type: news

The Next Five Years of PDUFA VI: Driving the availability of innovative treatments for patients
Yesterday, October 1, marked the first day of implementation for PDUFA VI, the next iteration of the Prescription Drug User Fee Act (PDUFA) and one of the best tools that the U.S. Food and Drug Administration (FDA) has for enhancing regulatory efficiency and encouraging innovative development of safe and effective new medicines for patients.  (Source: The Catalyst)
Source: The Catalyst - October 2, 2017 Category: Pharmaceuticals Authors: Bill Chin, M.D. Tags: PDUFA Source Type: news

4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report
In case you missed it, anew analysis from QuintilesIMS, which draws on theMedicines Use and Spending in the U.S. — A Review of 2016 and Outlook to 2021 report and theOutlook for Global Medicines Through 2021: Balancing Cost and Value, takes an in-depth look at the true drivers of U.S. medicine spending. (Source: The Catalyst)
Source: The Catalyst - September 28, 2017 Category: Pharmaceuticals Tags: drug cost out of pocket costs Source Type: news

Profiles in courage: Latinos in the fight against Alzheimer ’s
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomesguest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to share a blog post from Jason Resendez, Executive Director of theLatinosAgainstAlzheimer ’s Coalition, convened by UsAgainstAlzheimer ’s. (Source: The Catalyst)
Source: The Catalyst - September 28, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Alzheimer's Source Type: news

Biopharma leads sustained economic growth driven by IP-intensive industries
While the biopharmaceutical industry is the global leader in generating innovative medicines and technologies, lesser known is the industry ’s central role in sustaining economic growth. A recent study from NDP Analytics finds that intellectual property (IP)-intensive manufacturing industries have an outsized positive impact on the economy and support 57.6 million American jobs. The study also finds that the biopharmaceutical industry leads as a critical sector, driving economic progress and supporting quality jobs. (Source: The Catalyst)
Source: The Catalyst - September 26, 2017 Category: Pharmaceuticals Authors: Tim McClung Tags: Intellectual Property Manufacturing Source Type: news

Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
As part ofThe Value Collaborative,an initiative of America ’s biopharmaceutical companies, we recently hosted anevent withBloomberg about unlocking and supporting value in the future of health care. Breakthrough medicines are revolutionizing how we fight disease, but too often patients have to fight to access these treatments. We can improve access and affordability through market-based reforms such as moving toward a system that prioritizes results for patients. (Source: The Catalyst)
Source: The Catalyst - September 21, 2017 Category: Pharmaceuticals Tags: The Value Collaborative Source Type: news

More than 85 medicines in development for Alzheimer ’s disease
WhenBrian Kursonis started “blanking out” for moments at a time, a scan revealed plaques of a protein called amyloid in the brain, one sign of Alzheimer’s disease. A test of his spinal fluid found high levels of amyloid and tau, another protein linked to the condition. (Source: The Catalyst)
Source: The Catalyst - September 21, 2017 Category: Pharmaceuticals Tags: Medicines in Development Alzheimer's New Era of Medicine Source Type: news

The journey to better health care requires a holistic view
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to share a blog post from Dieter Weinand, Member of the Board of Management and President, Pharmaceuticals, Bayer. (Source: The Catalyst)
Source: The Catalyst - September 18, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Value PhRMA Member Company health care spending Value-Driven Health Care Source Type: news

What they are saying: Study on cancer R & D costs is not an accurate representation of marketplace
A recent study published inJAMA Internal Medicine provides flawed and inaccurate estimates of the significant research and development (R&D) investments made by biopharmaceutical companies to develop new cancer treatments and cures for patients. The study focuses on a selective sample of companies that have been successful, ignores significant investments in early stage R&D and relies on inaccurate assumptions regarding industry revenues. (Source: The Catalyst)
Source: The Catalyst - September 12, 2017 Category: Pharmaceuticals Tags: Research and Development cancer drug cost Market Distortions Source Type: news

Medicare Monday: Medicare Part D by the numbers
Getting back into the swing of things as Fall approaches? Here ’s some light Medicare reading! And if you need a refresher, you can go back to our ABC (and Ds) of Medicarepost: (Source: The Catalyst)
Source: The Catalyst - September 11, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

Working to harness the power of the body ’s own immune system
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.Today, we are pleased to share a blog post from Christina Trout, a research and drug discovery scientist at Celgene.The human body is comprised of many fascinating and complex...
Source: The Catalyst - September 7, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: GoBoldly Source Type: news

How biopharmaceutical collaboration is driving a new era of medicine
Biopharmaceutical innovation, coupled with technological advancements, has brought a new era of medicine transforming how we research and develop new medicines to benefit patients. (Source: The Catalyst)
Source: The Catalyst - September 7, 2017 Category: Pharmaceuticals Tags: Research and Development New Era of Medicine Source Type: news

Protect Your Health: Important Disaster Preparedness Tips for Harvey and Irma
It ’s clear that natural disasters, such as Hurricane Harvey and Irma, bring dangerous and destructive winds, rain and flooding. But the greatest threats of a natural disaster are not always immediately apparent. Harvey didn’t just destroy homes, stores and roads; the storm dismantled critical safe ty nets that we rely on every day, particularly for our health and medicines.  (Source: The Catalyst)
Source: The Catalyst - September 6, 2017 Category: Pharmaceuticals Authors: Nicole Louissaint Tags: Safety diabetes cancer Prescription Drug Safety Asthma heart disease Medication Adherence Source Type: news

Helping those affected by Hurricane Harvey
Given the unprecedented scale of the devastation and flooding caused by Hurricane Harvey, we wanted to provide information about the resources available for patients to access medicines as well as details about where to provide support and what some of America's biopharmaceutical companies are doing to respond to this tragedy. (Source: The Catalyst)
Source: The Catalyst - August 31, 2017 Category: Pharmaceuticals Tags: PhRMA Member Company Partnership for Prescription Assistance Source Type: news

Helping those affected by the 2017 hurricane season
This post has been updated as of 9/22/2017 to reflect relief efforts for Hurricanes Harvey, Irma and Maria.Given the unprecedented scale of the devastation and flooding caused by Hurricanes Harvey, Irma and Maria, we wanted to provide information about the resources available for patients to access medicines as well as details about where to provide support and what some of America's biopharmaceutical companies are doing to respond to this tragedy. (Source: The Catalyst)
Source: The Catalyst - August 31, 2017 Category: Pharmaceuticals Tags: PhRMA Member Company Partnership for Prescription Assistance Source Type: news

Helping those affected by Hurricanes Harvey and Irma
This post has been updated as of 9/14/2017 to reflect relief efforts related to both Hurricane Harvey and Hurricane Irma.Given the unprecedented scale of the devastation and flooding caused by Hurricanes Harvey and Irma, we wanted to provide information about the resources available for patients to access medicines as well as details about where to provide support and what some of America's biopharmaceutical companies are doing to respond to this tragedy. (Source: The Catalyst)
Source: The Catalyst - August 31, 2017 Category: Pharmaceuticals Tags: PhRMA Member Company Partnership for Prescription Assistance Source Type: news

SB 17 doesn ’t address pressing prescription drug transparency issues for CA voters
California ’s SB 17 is one of a number of bills relating to prescription drug transparency around prescription medicine costs that are wending their way through U.S. statehouses. (Source: The Catalyst)
Source: The Catalyst - August 30, 2017 Category: Pharmaceuticals Authors: Priscilla VanderVeer Source Type: news

Medicare Monday: Call for repeal of IPAB intensifies
Efforts to repeal the Independent Payment Advisory Board (IPAB) are gaining momentum as health care stakeholders and policymakers on both sides of the aisle continue tovoice their concerns over the board ’s broad, virtually unchecked powers. (Source: The Catalyst)
Source: The Catalyst - August 28, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday IPAB Source Type: news

Medicare Monday: What is the Extra Help program?
Medicare Part D ’s Extra Help program helps low-income beneficiaries better afford their medicines. In fact, millions of beneficiaries have received Extra Help in Part D. (Source: The Catalyst)
Source: The Catalyst - August 21, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Extra Help Program Source Type: news

Medicare Monday: Strengthening access to vaccines for seniors
This month, we ’re celebrating National Immunization Awareness Month! Although children may come to mind first when we think of vaccination, access to immunization is just as important for older Americans. (Source: The Catalyst)
Source: The Catalyst - August 14, 2017 Category: Pharmaceuticals Tags: Medicines in Development Vaccines Part D Medicare Medicare Monday Source Type: news

Medicare Monday: Part D premiums expected to drop in 2018
Great news for seniors and people living with disabilities who rely on Part D! Last week, the Centers for Medicare& Medicaid Services (CMS) announced thatMedicare Part D prescription drug plan premiums are projected to drop. CMS estimates the average monthly Part D premium in 2018 will be $33.50, about a dollar less than this year ’s average. (Source: The Catalyst)
Source: The Catalyst - August 7, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

ICYMI: New report outlines steps for greater transparency in health care
Last week, The Network for Excellence in Health Innovation (NEHI) released a new report that outlines steps for greater transparency in health care. The report states that helping consumers make well-informed decisions can lead to higher quality of care, greater patient satisfaction and better use of the nation ’s health care resources. (Source: The Catalyst)
Source: The Catalyst - August 4, 2017 Category: Pharmaceuticals Authors: Katie Koziara Tags: health insurance Source Type: news

PhRMA Supports President ’s Commission’s Holistic Approach on Opioid Crisis
Just about every day, I read a news story about the opioid crisis or talk to someone who has been personally impacted by addiction. According to the CDC, opioids, including prescription opioids and heroin, killed more than 33,000 people in 2015 - more than any year on record. Nearly half of all opioid overdose deaths involve a prescription opioid.  (Source: The Catalyst)
Source: The Catalyst - August 2, 2017 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Prescription Drug Safety Source Type: news

Medicare Monday: Medicare turns 52!
This weekend (July 30) marked 52 years since Medicare was signed into law by President Lyndon B. Johnson as a part of theSocial Security Act Amendments. To celebrate the occasion, we are taking a look at the ABC (and Ds) of Medicare:  (Source: The Catalyst)
Source: The Catalyst - July 31, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Part B Source Type: news

Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box
PhRMA president and CEO Stephen J. Ubl joined Squawk Box this morning to put medicine costs and spending in context, the biopharmaceutical supply chain and policy solutions to address cost concerns and continue U.S. leadership in medical innovation. (Source: The Catalyst)
Source: The Catalyst - July 31, 2017 Category: Pharmaceuticals Tags: drug cost Source Type: news

Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
The Bay Area in California has long been considered a nucleus of innovation, having produced groundbreaking inventions and discoveries over the last few decades – spanning nearly every industry, from medicine, technology and capital. (Source: The Catalyst)
Source: The Catalyst - July 31, 2017 Category: Pharmaceuticals Tags: New Era of Medicine Source Type: news

Biopharmaceutical industry policies aim to increase access to clinical trial data
Today, astudy published in the British Medical Journal (BMJ) sought to audit industry clinical trial disclosure and data sharing policies. The study, entitledPharmaceutical companies ’ policies on access to trial data, results, and methods: audit study, and authored by affiliates of the AllTrials organization, looked at company policies with regard to registration, methods and summary results, CSRS and individual patient data. (Source: The Catalyst)
Source: The Catalyst - July 27, 2017 Category: Pharmaceuticals Authors: Olivia Shopshear Tags: Clinical Trials Source Type: news

Opportunities to build upon enhanced competition for medicines in the marketplace
Last week, I presented at the U.S Food and Drug Administration ’s (FDA)public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical development and accelerating access to generic alternatives. The important discussion led by the FDA is part of an ongoing conversation being held across the health care spectrum on the importance of a competitive marketplace for biopharmaceuticals. (Source: The Catalyst)
Source: The Catalyst - July 27, 2017 Category: Pharmaceuticals Authors: David Korn Tags: Safety FDA Intellectual Property REMS Source Type: news

Finding cures for incurable diseases
By Sandra Raymond, president and CEO, The Lupus Foundation of America (Source: The Catalyst)
Source: The Catalyst - July 25, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Medicines in Development Lupus New Era of Medicine Source Type: news

Medicare Monday: How Part B has evolved over the years
With Medicare ’s birthday rapidly approaching (July 30!), today we’re highlighting a few of the ways reimbursement for physician-administered medicines under Part B has changed since it was first created in 1965 as part of theSocial Security Act Amendments and how this program works as a market-based system to manage costs and support beneficiary access to needed medicines. (Source: The Catalyst)
Source: The Catalyst - July 24, 2017 Category: Pharmaceuticals Tags: Value Medicare Medicare Monday Part B Source Type: news

Guest Post: Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to share a blog post from Professor Meir Pugatch, IPKM Professor of Valorisation, Entrepreneurship and Management at the University of Maastricht and Managing D...
Source: The Catalyst - July 24, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Economic Impact Intellectual Property Policy Solutions Source Type: news